Insulin Degludec Is Effective in Patients With Type 1 or Type 2 Diabetes After Switching Basal Insulin

November 6, 2017. This European, multicenter, retrospective chart review (EU-TREAT) found that switching patients with type 1 or type 2 diabetes (T1D, T2D) from other basal insulins to insulin degludec improved glycemic control while significantly reducing hypoglycemia risk at 6 months. For patients with T1D and T2D, A1C decreased by a mean of −0.20% (95% confidence interval [CI]: −0.24%, −0.17%) and −0.51% (95% CI: −0.58%, −0.43%), respectively, vs baseline (all P<0.001). The rate ratio of non-severe and severe hypoglycemia also decreased significantly for patients in both groups. Finally, total daily insulin dose was decreased for both T1D and T2D patients by −11% (P<0.001) and −3% (P<0.006), respectively. Clinical outcomes for both groups remained consistent at 12 months. Read the study abstract here.